Glaukos is moving forward with an FDA new drug application phase 3 clinical program for the iDose TR after finishing patient enrollment and randomization, according to a press release.
“We are excited to announce this important milestone for iDose TR, marking a critical step in bringing this promising technology one step closer to being able to safely provide sustained glaucoma pharmaceutical therapy and tackle the significant problem of patient nonadherence to topical glaucoma medication regimens,” Thomas Burns, Glaukos president and CEO, said in the release.
Two prospective,